CRIS insider trading
NasdaqCM HealthcareCURIS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CURIS INC
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Company website: www.curis.com
CRIS insider activity at a glance
FilingIQ has scored 134 insider transactions for CRIS since Jan 26, 2015. The most recent filing in our index is dated Mar 31, 2026.
Across the full history, 4 open-market purchases
and 38 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CRIS insider trades is 54.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CRIS?
- FilingIQ tracks 134 Form 4 insider transactions for CRIS (CURIS INC), covering filings from Jan 26, 2015 onwards. 31 of those were filed in the last 90 days.
- Are CRIS insiders net buyers or net sellers?
- Across the full Form 4 history for CRIS, 4 transactions (3%) were open-market purchases and 38 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CRIS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CRIS in?
- CURIS INC (CRIS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $15.34M.
Methodology & sources
Every CRIS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.